The endocannabinoid system targeted therapeutics market is projected to grow at an annualized rate of ~30%
RootsAnalysishas done a detailed study on Endocannabinoid System Targeted Therapeutics Market,2020-2030“ covering key aspects of theindustry’s evolution and identifying potential future growth opportunities.
To order this 250+ page report,which features 140+ figures and 170+ tables, please visit https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Key Market Insights
§ More than 65 industry players across the world arepresently engaged in evaluating the clinical applications of over180cannabinoid-derivatives that target the human endocannabinoid signaling system
§ The pipeline features a variety of marketed / clinical stagetherapies, being investigated for a wide range of target disease indicationsand designed for administration via different routes
§ The geographical landscape of this industry is likely toevolve in the next few years as federal authorities legalize the use of medicalcannabis across multiple countries
§ Despite the associated stigma, many organizations haveextended financial support to aid research efforts in this domain; the focus ison understanding the clinical benefits of endocannabinoid signaling in differentdiseases
§ The growing interest in this field is also reflected by the170+ partnerships that have been signed in the last five years, involving bothinternational and indigenous stakeholders, across different geographicalmarketplaces
§ Presently, North American companies seem to beconsolidating their presence indigenously, mostly through strategicacquisitions; key value drivers behind such deals include product andgeographical expansion
§ Future market size, based on revenue generation potentialof marketed and late stage therapies, is anticipated to be distributed across avariety of therapeutic areas, target receptors and key geographical regions
For more information, please visit “EndocannabinoidSystem Targeted Therapeutics Market, 2020-2030.“
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Neuropharmacology andWorking Mechanism of the Endocannabinoid System
3.3. Potential TherapeuticApplications of Cannabinoids
3.4. Legal Aspects andRegulations
3.5. Existing Challenges
3.6. Future of CannabinoidTherapies
4. MARKET LANDSCAPE:ENDOCANNABINOID SYSTEM TARGETED THERAPEUTICS
4.1. Chapter Overview
4.2. Drugs TargetingEndocannabinoid System: Marketed and Development Pipeline
4.2.1. Analysis by Phase ofDevelopment
4.2.2. Analysis by TargetTherapeutic Area
4.2.3. Analysis by Route ofAdministration
4.2.4. Analysis by DosingFrequency
4.2.5. Analysis by TargetReceptor
4.2.6. Grid Analysis:Distribution by Phase of Development, Target Therapeutic Area and TargetReceptor
4.3. Endocannabinoid SystemTargeted Therapeutics: List of Developers
4.3.1. Analysis by Year ofEstablishment
4.3.2. Analysis by Company Sizeand Geographical Location
4.4. List of CannabisSuppliers
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. GW Pharmaceuticals
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Endocannabinoid TargetingTherapeutics Portfolio
5.2.4. Recent Developments andFuture Outlook
5.3. Corbus Pharmaceuticals
5.3.1. Company Overview
5.3.2. Endocannabinoid TargetingTherapeutics Portfolio
5.3.3. Recent Developments andFuture Outlook
5.4. Tilray
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Endocannabinoid TargetingTherapeutics Portfolio
5.4.3.2. RecentDevelopments and Future Outlook
5.5. Pure Green
5.5.1. Company Overview
5.5.2. Endocannabinoid TargetingTherapeutics Portfolio
5.6. Tetra Bio-Pharma
5.6.1. Company Overview
5.6.2. Endocannabinoid TargetingTherapeutics Portfolio
5.6.3. Recent Developments andFuture Outlook
5.7. Botanix Pharmaceuticals
5.7.1. Company Overview
5.7.2. Endocannabinoid TargetingTherapeutics Portfolio
5.7.3. Recent Developments andFuture Outlook
5.8. Kalytera Therapeutics
5.8.1. Company Overview
5.8.2. Endocannabinoid TargetingTherapeutics Portfolio
5.8.3. Recent Developments andFuture Outlook
5.9. Therapix Biosciences
5.9.1. Company Overview
5.9.2. Endocannabinoid TargetingTherapeutics Portfolio
5.9.3. Recent Developments andFuture Outlook
5.10. Zelira Therapeutics
5.10.1. Company Overview
5.10.2. Endocannabinoid TargetingTherapeutics Portfolio
5.10.3. Recent Developments andFuture Outlook
5.11. Avicanna
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. Endocannabinoid TargetingTherapeutics Portfolio
5.11.4. Recent Developments andFuture Outlook
5.12. GB Sciences
5.12.1. Company Overview
5.12.2. Financial Information
5.12.3. Endocannabinoid TargetingTherapeutics Portfolio
5.12.4. Recent Developments andFuture Outlook
6. ACADEMIC GRANTS ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Endocannabinoid SystemTargeted Therapeutics: List of Grants Awarded by National Institutes of Health(NIH)
6.3.1. Analysis by Year of GrantAward
6.3.2. Analysis by AmountAwarded
6.3.3. Analysis by AdministeringInstitute Center
6.3.4. Analysis by FundingInstitute Center
6.3.5. Analysis by SupportPeriod
6.3.6. Analysis by FundingInstitute Center and Support Period
6.3.7. Analysis by Type of GrantApplication
6.3.8. Analysis by Purpose ofGrant Award
6.3.9. Analysis by GrantMechanism
6.3.10. Word Cloud Analysis:Emerging Focus Areas
6.3.11. Analysis by Study SectionInvolved
6.3.12. Popular NIH Departments:Analysis by Number of Grants
6.3.13. Analysis by Types ofRecipient Organizations
6.3.14. Prominent ProgramOfficers: Analysis by Number of Grants
6.3.15. Popular RecipientOrganizations: Analysis by Number of Grants
6.3.16. Regional Analysis ofRecipient Organizations
7. PARTNERSHIPS ANDCOLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Endocannabinoid TargetedTherapeutics: List of Partnerships and Collaborations
7.3.1. Analysis by Year ofPartnership
7.3.2. Analysis by Type ofPartnership
7.3.3. Analysis by Type ofPartnership and Target Disease Indication
7.3.4. Analysis by Year ofPartnership and Type of Partner
7.3.5. Most Active Players:Analysis by Number of Partnerships
7.3.6. Regional Analysis
7.3.7. Intercontinental andIntracontinental Agreements
8. MERGERS AND ACQUISITIONS
8.1. Chapter Overview
8.2. Acquisition Models
8.3. Endocannabinoid TargetedTherapeutics: Mergers and Acquisitions
8.3.1. Cumulative Year-wiseTrend
8.3.2. Analysis by Type ofAcquisition
8.3.3. Year of Acquisitions andDeal Financials
8.3.4. Geographical Analysis ofMergers and Acquisitions
8.3.5. Ownership Change Matrix
8.3.6. Most Active Players:Analysis by Number of Acquisitions
8.3.7. Key Value Drivers
8.3.8. Valuation Analysis:Acquisition Deal Multiples
9. DRUG DEVELOPMENTSTRATEGY ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Strategies Adopted byLate-Stage Drug Candidate Developers
10. MARKET FORECAST ANDOPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology andKey Assumptions
10.3. Global EndocannabinoidTargeted Therapeutics Market, 2020-2030
10.4. Global EndocannabinoidTargeted Therapeutics Market: Individual Product Sales Forecasts
10.4.1. EPIDIOLEX® (GWPharmaceuticals)
10.4.1.1. Target Patient Population
10.4.1.2. Sales Forecast
10.4.2. Sativex® (GWPharmaceuticals)
10.4.2.1. Target Patient Population
10.4.2.2. Sales Forecast
10.4.3. PPP011 (Caumz)
10.4.3.1. Target Patient Population
10.4.3.2. Sales Forecast
10.4.4. Lenabasum
10.4.4.1. Target Patient Population
10.4.4.2. Sales Forecast
10.4.5. CannEpil™
10.4.5.1. Target Patient Population
10.4.5.2. Sales Forecast
10.5. Global EndocannabinoidSystem Targeted Therapeutics Market: Focus on CB1, CB2 and TRPV1 Receptors
10.6. Global EndocannabinoidSystem Targeted Therapeutics Market: Distribution by Region, 2020-2030
10.6.1. Endocannabinoid SystemTargeted Therapeutics Market in North America, 2020-2030
10.6.2. Endocannabinoid SystemTargeted Therapeutics Market in Europe, 2020-2030
10.6.3. Endocannabinoid SystemTargeted Therapeutics Market in Asia-Pacific, 2020-2030
10.6.4. Endocannabinoid SystemTargeted Therapeutics Market in Rest of the World, 2020-2030
10.7. Global EndocannabinoidSystem Targeted Therapeutics Market: Distribution by Target Therapeutic Area,2020-2030
10.7.1. Global EndocannabinoidSystem Targeted Therapeutics Market for Autoimmune Diseases, 2020-2030
10.7.2. Global EndocannabinoidSystem Targeted Therapeutics Market for Genetic Disorders, 2020-2030
10.7.3. Global EndocannabinoidSystem Targeted Therapeutics Market for Neurological Disorders, 2020-2030
10.7.4. Global EndocannabinoidSystem Targeted Therapeutics Market for Pain Disorders, 2020-2030
10.8. Global EndocannabinoidSystem Targeted Therapeutics Market: Distribution by Route of Administration
10.8.1. Global EndocannabinoidSystem Targeted Therapeutics Market for Oral Therapies, 2020-2030
10.8.5. Global EndocannabinoidSystem Targeted Therapeutics Market for Inhalation Therapies, 2020-2030
11. CONCLUDING REMARKS
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2 Zelira Therapeutics US
12.2.1. Company Snapshot
12.2.2. Interview Transcript:Oludare Odumosu, Chief Executive Officer
12.3. GB Sciences
12.3.1. Company Snapshot
12.3.2. Interview Transcript:Andrea Small-Howard, Chief Scientific Officer
12.4. Tetra Bio-Pharma
12.4.1. Company Snapshot
12.4.2. Interview Transcript:Steeve Néron, Chief Operating Officer
12.5 Vireo Health
12.5.1. Company Snapshot
12.5.2. Interview Transcript:Stephen Dahmer, Chief Medical Officer
13. APPENDIX 1: TABULATEDDATA
14. APPENDIX 2: LIST OFCOMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
